What Biotechnology Stocks Will Be Next To Enjoy The Bull Market?

CORAL GABLES, FL / ACCESSWIRE / May 29, 2015 / The Nasdaq Biotechnology Index is up significantly over the last 5 years with a good majority of positive momentum kicking in during the last 18 months. Since levels hovering around 830 this time in 2010, you can quickly begin to see the massive growth that this market has seen especially since the NBI hit over 3,900 this year. The sharpest increase on the index hasn’t been until recently from 2014- present and with the amount of IPO’s and mergers & acquisitions buzz, biotech stocks have captured the interests of many. Oncothyreon, Inc. (ONTY), Amarin Corp. Plc (AMRN), and Accurexa Inc. (ACXA) have begun to become more familiar with today’s biotech investors.

Oncothyreon, Inc. announced this week that Robert Kirkman, M.D., President and Chief Executive Officer, is scheduled to present at the Jefferies 2015 Healthcare Conference in June. Share price of Oncothyreon has increased by as much as 158% since the first of May. The Company has two drug candidates in development, ONT-10, a therapeutic vaccine targeting MUC1, a glycoprotein amplified in most solid epithelial tumor cancers and common non-solid tumors, and ONT-380, an orally active, reversible and small molecule selective inhibitor of human epidermal growth factor receptor 2 (HER2). HER2 is also amplified in many types of cancers, including breast, ovarian and stomach.

Amarin Corp. Plc also announced this week that Amarin’s President and Chief Executive Officer, John F. Thero, is scheduled to present a general company update at the Jefferies 2015 Global Healthcare Conference. Though some are speculating on short interest in Amarin, price movement has suggested the opposite to that over the last 3 days. Since opening the week at $1.90, shares of AMRN have jumped by as much as 47% following Thursday highs of $2.80. Amarin focuses more on cardiovascular health. Currently the company’s first product Vascepa(R) (icosapent ethyl) capsules, is a highly pure EPA omega-3 prescription product.

Seen as newer to the street, ironically, Accurexa Inc has been recently featured on “New To The Street,” a financial broadcast, which airs in New York, LA, Philadelphia, Boston and Miami. George Yu, CEO, Accurexa, Inc. spoke about the Company’s technology for brain cancer and stem cell therapy using its BranchPoint Device. Earlier this year, Accurexa was qualified as a small business by the FDA under its Medical Device User Fee Amendment and allows the company to take advantage of reduced or waived fees for medical device submissions made during fiscal year 2015. Though this is new to the market, interest surrounding its BranchPoint Device has begun to take hold. The device was invented to deliver therapeutics, such as stem cells or gene therapy vectors, through the radial deployment of a flexible catheter to specific brain target areas through a single brain penetration.

The benefits of this device have been seen in certain studies. In fact, according to Accurexa, the current standard of care is the use of straight, rigid needles, that require surgeons to penetrate the brain several times for delivering therapeutics and can actually increase the risk of bleeding, stroke and reflux of therapeutics back out to the brain surface. An animal study* at the University of California, San Francisco demonstrated that the use of a straight needle was associated with reflux of at least 75% of the infusion while no reflux was found with the BranchPoint device.

* Silvestrini MT, Yin D, Coppes VG, Mann P, Martin AJ, Larson PS, Starr PA, Gupta N, Panter SS, Desai TA, Lim DA. Radially branched deployment for more efficient cell transplantation at the scale of the human brain. Stereotact Funct Neurosurg. 2013;91(2):92-103.

ABOUT US:

www.DailyStockReporter.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals www.DailyStockReporter.com is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. You can subscribe to the www.DailyStockReporter.com newsletter and start receiving daily alerts. To subscribe by phone and receive messages directly to a mobile phone, text the phrase “StockAlerts” to 63566.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements.

EGM FIRM INC which owns www.DailyStockReporter.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release.
EGM FIRM INC, which owns www.DailyStockReporter.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice.

EGM FIRM INC which owns www.DailyStockReporter.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

CONTACT:

Company: EGM FIRM INC.
Contact Email: adam@egmfirm.com

SOURCE: BiotechStocks.com

ReleaseID: 429353